[Intensified risk monitoring of new drugs in general practice by the established physician].
Hanpft
R
R
Hannig
M
M
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005860:Germany, West; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D059005:Topoisomerase II Inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000900:Anti-Bacterial Agents; D006635:Histamine H2 Antagonists; D059005:Topoisomerase II Inhibitors
Intensivierte Risikoüberwachung neuer Arzneimittel in der Praxis des niedergelassenen Arztes.